Adverts

Open Access Articles- Top Results for Elzasonan

Elzasonan

</th></tr>
Elzasonan
File:Elzasonan structure.svg
Systematic (IUPAC) name
4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one
Clinical data
  • Uncontrolled
Oral
Identifiers
220322-05-4 7pxY
None
PubChem CID 19544192
UNII 933PJL964R 7pxY
Chemical data
Formula C22H23Cl2N3OS
448.4085 g/mol
 14pxY (what is this?)  (verify)

Elzasonan (CP-448,187) is a selective 5-HT1B and 5-HT1D receptor antagonist that was under development by Pfizer for the treatment of depression but was discontinued, possibly due to poor efficacy.[1][2][3][4][5] By preferentially blocking 5-HT1B and 5-HT1D autoreceptors, elzasonan is thought to enhance serotonergic innervations originating from the raphe nucleus, thereby improving signaling to limbic regions like the hippocampus and prefrontal cortex and ultimately resulting in antidepressant effects.[3]

See also

References